HORMONE THERAPY, REVISITED
The Hormone Replacement Therapy Study That Scared a Generation of Women—and What We Know Now
Bone density can drop fastest in the years right after your last period. What a DEXA scan tells you, and when to get one.
By Phillip Gallegos, MD
Physician and Co-founder, Thrive Medicine Clinic
For more than two decades, one study has shaped how millions of women—and many of their healthcare providers—think about hormone replacement therapy (HRT).
In 2002, results from the Women’s Health Initiative (WHI) made national headlines. Women were warned that HRT could increase the risk of breast cancer, heart disease, stroke, and blood clots.
The reaction was immediate. Many women stopped taking hormones. Physicians became reluctant to prescribe them. And an entire generation entered menopause believing that hormone therapy was simply dangerous.
More than 20 years later, we know the story is much more complicated.
What did the WHI actually study?
One important detail was largely lost in the headlines: the average woman participating in the WHI hormone trials was about 63 years old—more than a decade beyond the average age of natural menopause.
That matters. A woman beginning hormone therapy in her late 40s or early 50s as menopause symptoms appear is very different from a woman starting treatment many years after menopause.
The most publicized WHI trial also studied a specific hormone combination: oral conjugated equine estrogens, a type of estrogen originally derived from horses, combined with medroxyprogesterone acetate, a synthetic form of progesterone known as a progestin.
The study found small increases in several health risks, including heart disease, stroke, blood clots, and breast cancer. It also found benefits, including fewer hip fractures.
Unfortunately, a much simpler message reached the public: HRT is dangerous.
We now understand that hormone therapy cannot be reduced to one medication, one dose, or one risk profile.
When you start hormone therapy matters
One of the biggest lessons learned since the WHI is that timing matters.
Current menopause guidance recognizes that, for most healthy women who are younger than 60 or within about 10 years of menopause and do not have medical reasons that make hormone therapy inappropriate, the balance of benefits and risks is generally favorable when treating bothersome menopause symptoms.
Starting hormone therapy much later in life requires a different conversation because a woman’s underlying risks for cardiovascular disease, blood clots, and other conditions change as she ages.
This is why asking, “Is HRT safe?” may be the wrong question.
A better question is: “Is hormone therapy appropriate for me, at this point in my life, and what type of treatment is best for me?”
What about breast cancer?
This is understandably one of women’s greatest concerns.
Long-term follow-up from the WHI revealed something that received far less attention than the original headlines: the two hormone-treatment groups did not have the same breast cancer outcomes.
Women who had previously undergone a hysterectomy and received estrogen alone actually had fewer breast cancer diagnoses and fewer deaths from breast cancer than women who received a placebo.
Women who received the combination of estrogen plus the synthetic progestin had a higher rate of breast cancer.
This distinction is important. It demonstrates why saying simply “HRT causes breast cancer” does not accurately describe the evidence.
Menopause medicine has evolved
Today’s menopause care is far more individualized.
A knowledgeable provider considers a woman’s age, symptoms, time since menopause, medical and family history, breast and cardiovascular health, whether she still has her uterus, and her personal goals.
The type of hormone, dose, and how it is delivered—such as by mouth or through the skin—can also matter.
Hormone therapy remains the most effective treatment for hot flashes and night sweats associated with menopause. It can also help prevent bone loss and fractures and, for appropriately selected women, can significantly improve quality of life.
In 2026, the U.S. Food and Drug Administration approved major changes to the labeling of menopausal hormone therapies, including removing references to cardiovascular disease, breast cancer, and probable dementia from the boxed warnings of products receiving the updated labels. The decision followed a comprehensive review of the scientific evidence and represents a remarkable change from the fear that followed the WHI more than two decades ago.
It’s time for a better conversation
The lesson of the WHI should not be that hormone therapy is dangerous.
It also should not be that hormone therapy is right for every woman.
The lesson is that menopause care deserves individualized, evidence-informed medicine—not fear and not one-size-fits-all treatment.
Women deserve the opportunity to discuss their symptoms, health history, goals, potential benefits, and individual risks with a provider knowledgeable about menopause.
For many women navigating perimenopause and menopause today, hormone therapy deserves to be part of that conversation. If you're ready to start it, the team at Thrive Medicine Clinic in Houston Heights offers menopause and hormone consultations in person and by telehealth across Texas.
What to ask
-
Based on my age, symptoms, and how long it has been since my last period, am I a candidate for hormone therapy?
-
What in my personal and family history, including breast cancer, heart disease, stroke, or blood clots, affects my options?
-
Since I do or don't still have my uterus, would I need estrogen alone or estrogen with a progestogen?
-
Would a patch, gel, or other non-oral form make sense for me, and why?
-
What dose would we start with, and how will we know whether it is working?
-
How often should we review whether I still need it?
-
If hormone therapy isn't right for me, what other treatments could help my symptoms?
The short version
A 2002 study led millions of women to stop hormone therapy, but the women it studied averaged 63, more than a decade past typical menopause, and took one specific hormone combination. Two decades of follow-up show the risks depend heavily on age, timing, and the type of hormone used. For most healthy women under 60 or within about 10 years of menopause, the benefits for bothersome symptoms generally outweigh the risks, and in 2026 the FDA removed breast cancer, heart disease, and dementia from the boxed warning on updated labels.
​
The better question is not whether HRT is safe, but whether it is right for you, now, and in what form.
This article is general education, not medical advice. Talk with a qualified healthcare provider about your own health.
Dr. Gallegos is co-founder of Thrive Medicine Clinic, which provides hormone therapy. Thrive Medicine Clinic is a sponsor of Second Spring.
Sources
Women's Health Initiative — Principal results, JAMA (2002) — Original findings; participants' average age of 63; conjugated equine estrogens with medroxyprogesterone acetate; increased risks alongside fewer hip fractures
​
Women's Health Initiative — Extended follow-up, JAMA (2013) — Long-term outcomes during and after treatment; results differed by age at the start of therapy
The Menopause Society — 2022 Hormone Therapy Position Statement — Favorable benefit-risk under 60 or within 10 years of menopause; most effective treatment for hot flashes; individualized dose, type, and route
Women's Health Initiative — Breast cancer long-term follow-up, JAMA (2020) — Estrogen alone linked to lower breast cancer incidence and mortality; estrogen plus progestin linked to higher incidence
U.S. Food and Drug Administration — Labeling changes approved (February 2026) — Cardiovascular disease, breast cancer, and probable dementia removed from the boxed warning on updated labels
U.S. Department of Health and Human Services — Removal of boxed warnings announced (November 2025) — Comprehensive evidence review behind the label changes
